Zonipraz-ED Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), irreversibly inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant reduction in gastric acid secretion. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance. Together, these agents provide symptomatic relief by addressing both acid hypersecretion and impaired gastric motility. Zonipraz-ED is indicated for the treatment of GERD, erosive esophagitis, and functional dyspepsia, particularly in patients exhibiting delayed gastric emptying or associated nausea. It should be used under medical supervision, with caution in patients with cardiac arrhythmias or prolonged QT interval due to Domperidone’s potential cardiotoxicity. Dosage adjustments may be necessary in hepatic impairment. Common adverse effects include headache, dry mouth, and abdominal discomfort. Zonipraz-ED Capsule SR offers a comprehensive approach to upper GI tract disorders by combining acid suppression with prokinetic activity.